Drug interaction risks with fluvoxamine plus bupropion
Fluvoxamine inhibits CYP2D6 activity in vitro, which may affect bupropion metabolism via inhibition of bupropion hydroxylation in vitro. [1] Bupropion inhibits CYP2D6 and can increase concentrations of other CYP2D6 substrates, but this is a separate directionality from the fluvoxamine–bupropion interaction. [2] The combination increases clinical concern for bupropion-related adverse effects, particularly seizure risk, because bupropion has dose-related seizure risk and caution is required when coadministered with agents that can affect seizure threshold. [3]
Pharmacokinetic interaction risks
Fluvoxamine is reported to inhibit CYP2D6-related hydroxylation of bupropion in vitro, with no clinical pharmacokinetic studies performed to quantify the effect in patients. [1] No specific dosing adjustment for bupropion is provided in labeling for coadministration with fluvoxamine, so management is based on clinical response and tolerability. [1]
Pharmacodynamic interaction risks (CNS adverse effects)
Bupropion should be used with extreme caution when coadministered with other drugs that lower seizure threshold because low initial doses and gradual titration are recommended. [3] Fluvoxamine has multiple CNS drug interaction warnings and is associated with reports of seizures in combination with other serotonergic agents in product information, which can increase the clinical salience of seizure monitoring when used with bupropion. [4]
Recommended dosing adjustments strategy
Bupropion dose should be initiated at the lower end of the approved range when any interacting drug could increase bupropion exposure or increase risk of adverse CNS effects. [1] Bupropion dose increases should be performed gradually based on tolerability, because caution and gradual titration are recommended when seizure-threshold risk is increased with concomitant medications. [3] The maximum recommended daily bupropion dose should not be exceeded. [1] If bupropion is being added to therapy with fluvoxamine and adverse effects occur (especially neurologic symptoms), bupropion dose reduction should be considered based on clinical tolerability because the interaction effect magnitude is not established in clinical studies. [1]
Dosing adjustments for CYP2D6 substrates (management of downstream interactions)
Bupropion should be treated as a CYP2D6 inhibitor because coadministration with CYP2D6 substrates can increase exposure of those substrates. [2] When bupropion is coadministered with CYP2D6 substrates, the concomitant CYP2D6 substrate dose should be initiated at the lower end of the dose range, and consideration should be given to decreasing the dose of the original medication, particularly for drugs with narrow therapeutic index. [2]
Practical monitoring points during coadministration
Neurologic monitoring for seizure symptoms and other CNS adverse effects should be emphasized because seizure-threshold risk is a core safety concern for bupropion and is specifically addressed in labeling for cautious coadministration with interacting agents. [3] Monitoring for adverse effects related to increased exposure of bupropion should be prioritized because the fluvoxamine effect on bupropion hydroxylation is supported in vitro and lacks clinical quantification. [1]
Key labeling-supported interaction directionality
Fluvoxamine–bupropion: possible increase in bupropion exposure via inhibition of bupropion hydroxylation in vitro, without clinical PK studies to guide a specific numeric dose adjustment. [1] Bupropion–other drugs: increased concentrations of CYP2D6 substrates because bupropion inhibits CYP2D6, with dose reduction or lower-start dosing recommended for affected concomitant drugs. [2]
Sources and cited labeling
- Fluvoxamine inhibition of bupropion hydroxylation in vitro and absence of clinical studies to evaluate this finding. [1]
- Bupropion inhibition of CYP2D6 and guidance to initiate CYP2D6 substrate dosing at the lower end and consider dose reduction for narrow therapeutic index drugs. [2]
- Bupropion seizure-threshold warning with recommendation for extreme caution, low initial doses, and gradual titration with interacting agents. [3]